Overall, the reviewers wrote, most IBD therapies “appear safe and effective when used in chronic kidney disease, including on ...
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for ...
Inflammatory bowel disease and elevated BMI may play causal roles in hidradenitis suppurativa, results of a Mendelian ...
Many patients with inflammatory bowel disease (IBD) suffer from abdominal pain even between acute inflammatory flare-ups.
No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...
Studies presented at the ASH Annual Meeting 2025 highlighted a novel prognostic approach and emerging treatment strategies in lymphoma.
Venous thromboembolism more than doubles all-cause mortality among patients with IBD and triples IBD-related mortality.
Disease disclosure helps mediate the effect of discrimination on internalized stigma among individuals with IBD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback